1989
DOI: 10.1200/jco.1989.7.11.1667
|View full text |Cite
|
Sign up to set email alerts
|

Use of CA-125 to predict survival of patients with ovarian carcinoma. North Thames Cooperative Group.

Abstract: The prognostic value of serum CA-125 measurements was assessed in 54 patients with advanced ovarian adenocarcinoma. All patients received a minimum of two courses of carboplatin as part of the North Thames Cooperative Group trial. With a minimum follow-up of 6 months, 37 patients (69%) have clinical evidence of progressive disease and 28 have died. The absolute prechemotherapy level of CA-125 was of no value in predicting which patients would develop progressive disease. However, the change in CA-125 levels fr… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

4
35
1
3

Year Published

1992
1992
2012
2012

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 75 publications
(43 citation statements)
references
References 0 publications
4
35
1
3
Order By: Relevance
“…Observations by Lavin et al, indicated that a failure of CA 125 to regress to normal after three courses of chemotherapy, predicted persistent disease after completion of therapy (Lavin et al, 1987). In addition, the percentage change after one course of chemotherapy was reported to be related to progression-free survival (Rustin et al, 1989) although this was not confirmed by others (Redman et al, 1990).…”
mentioning
confidence: 67%
“…Observations by Lavin et al, indicated that a failure of CA 125 to regress to normal after three courses of chemotherapy, predicted persistent disease after completion of therapy (Lavin et al, 1987). In addition, the percentage change after one course of chemotherapy was reported to be related to progression-free survival (Rustin et al, 1989) although this was not confirmed by others (Redman et al, 1990).…”
mentioning
confidence: 67%
“…Even more alarmingly, many reports have questioned or rejected a correlation between a proposed biomarker and clinical outcome. Doubts were raised regarding the markers CA125 (Cruickshank et al 1987, van der Burg et al 1988, Rustin et al 1989, Sevelda et al 1989, cyclin D1 (Masciullo et al 1997, Dhar et al 1999, p16 (Milde-Langosch et al 2003, Khouja et al 2007), p21 (Baekelandt et al 1999, Levesque et al 2000, Schuyer et al 2001, p27 (Schmider et al 2000), p53 (Smith-Sorensen et al 1998, Wang et al 2004, Green et al 2006, Bcl-xl (Baekelandt et al 2000), cIAP (Kleinberg et al 2007), survivin (Cohen et al 2003, Ferrandina et al 2005, hTERT (Wisman et al 2003, Widschwendter et al 2004), ERBB1 (Berchuck et al 1991, Meden et al 1995, Nielsen et al 2004, and ERBB2 (Rubin et al 1993, Meden et al 1995, Ross et al 1999, Nielsen et al 2004, Riener et al 2004.…”
Section: Introductionmentioning
confidence: 99%
“…Este marcador puede estar elevado en otras neoplasias como adenocarcinomas (mama, pulmón, de origen digestivo), linfomas, leiomiosarcomas o melanomas, así como en procesos patológicos benignos como patología ginecológica (tumores benignos, salpingitis agudas o crónicas, abscesos tuboováricos, endometriosis), hepatopatías (granulomatosis hepática, hepatitis crónica alcohólica o vírica), pancreatitis, insuficiencia renal, derrame pericárdico o pleural, sarcoidosis, tuberculosis peritoneal, colagenosis, procedimientos quirúrgicos o que causan una rotura traumática del peritoneo, como la diálisis peritoneal 2,3 . Una utilidad potencial de CA 12-5 es el valor de este marcador como factor pronóstico de supervivencia en el carcinoma epitelial de ovario 4,5 . Cuando el CA 12-5 no desciende a valores normales tras los tres primeros ciclos de quimioterapia, las posibilidades de alcanzar una respuesta patológica completa son remotas.…”
Section: Discussionunclassified